SEC Form 4 · accession 0001179110-18-006018

Traws Pharma, Inc. · TRAW

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Apr 27, 2018

Accepted (ET)

May 1, 2018 · 6:34 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001130598

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F3	Apr 27, 2018	P$0	2,211,765	—	A	3,192,438	I	By the Michael and Jane Hoffman 2013 Descendants Trust
Common Stock^F3	holding	—	—		—	8,453	I	By the Michael and Jane Hoffman 2013 Descendants Trust(Non-GST Exempt Trust)
Common Stock	holding	—	—		—	1,876	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Warrant (right to purchase)^F1,F3,F2	$0.425	Apr 27, 2018	P	2,211,765	A	Apr 27, 2018	—	Series B Convertible Preferred Stock	55,294	2,211,765	I

F1The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315).
F2The warrants are exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and will expire on the 18-month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware.
F3These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust.